Credit: vir.bio
The company Vir Biotechnology Inc. may be a home run hit. This company as of right now is being valued at 5 times earnings (P/E of 5). It is true that its coronavirus has been pulled momentarily but at a higher dose may get reapproved. When the drug was approved in the last quarter of 2021 the company made revenue of $812 million and after tax profit (net income) of $525 million USD. Right now the company is being valued at $2.88 billion USD. Vir Biotechnology is backed by Bill Gates, one of the richest men in the world.
If the company makes $500 million USD a quarter for 4 quarters, the P/E ratio (valuation of the company) will be less than 2 ($500 million x 4 quarters x 2 years = $4 billion USD, a higher valuation than the company right now. The company also has $708 million USD in cash and only $133 million USD in debt.
The company is in phase 2 trials for a Hepatitis B treatment that may cure the disease. Furthermore, it is in phase 1 trials for a treatment for Influenza A (the flu) as well as in phase 1 trials for a treatment for HIV.
Vir Biotechnology Inc symbol on the NASDAQ is VIR.
This material has been prepared by Upandcomingproducts.com. This document is for information and illustrative purposes only and does not purport to show actual results. It is not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action. Opinions expressed herein are current opinions as of the date appearing in this material only and are subject to change without notice. Reasonable people may disagree about the opinions expressed herein. In the event any of the assumptions used herein do not prove to be true, results are likely to vary substantially. All investments entail risks. There is no guarantee that investment strategies will achieve the desired results under all market conditions and each investor should evaluate its ability to invest for a long term especially during periods of a market downturn. No representation is being made that any account, product, or strategy will or is likely to achieve profits, losses, or results similar to those discussed, if any. No part of this document may be reproduced in any manner, in whole or in part, without the prior written permission of Upandcomingproducts.com , other than to your employees. This information is provided with the understanding that with respect to the material provided herein, that you will make your own independent decision with respect to any course of action in connection herewith and as to whether such course of action is appropriate or proper based on your own judgment, and that you are capable of understanding and assessing the merits of a course of action. Upandcomingproducts.com does not purport to and does not, in any fashion, provide broker/dealer, consulting or any related services. You may not rely on the statements contained herein. Upandcomingproducts.com shall not have any liability for any damages of any kind whatsoever relating to this material. You should consult your advisors with respect to these areas. By accepting this material, you acknowledge, understand and accept the foregoing.
0 Comments